# A Study of ARRY-520 in Patients With Advanced Cancer

> **NCT00462358** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 41 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ARRY-520, KSP(Eg5) inhibitor; intravenous
- **DRUG:** Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

## Key facts

- **NCT ID:** NCT00462358
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00462358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00462358, "A Study of ARRY-520 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00462358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*